Rituximab and RASi in Patients with IgAN

Korábbi kezelés

• 5. A history of active systemic infection or severe infection occurred one month before enrollment.
• 7. Current or recent ( within 30 days ) exposure to any research drug.
• 10. Continuous use of hormones or other immunosuppressive therapy in the past 6 months;

Más betegség

• 1. Evidence of the use of glucocorticoids for immunosuppressive therapy, such as: nephrotic syndrome, pathology for small lesions with IgA nephropathy. or the proportion of crescents confirmed by renal biopsy within 12 months was more than 50 %.
• 2. Clinical confirmation of cirrhosis, chronic active liver disease, or hepatitis B, C, or HIV which can detect viral replication;
• 3. Clinically confirmed IgA nephropathy secondary to systemic diseases such as systemic lupus erythematosus, allergic purpura.
• 8. Patients with allergic reactions to rituximab and / or known allergic reactions.
• 11. Accompanying or past malignant tumors, except for fully treated skin basal or squamous cell carcinoma or cervical carcinoma in situ;
• 12. History of psychosis may interfere with normal participation in this study;
• 13. Patients with major heart or lung diseases (including obstructive pulmonary disease);
• 14. In acute and chronic tuberculosis infection period (tuberculin test positive, chest X-ray suspected tuberculosis patients);
• 15. Patients with history of immunodeficiency, including other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;

Laborértékek

• 9. Laboratory tests meeting the following criteria should be excluded:
  • (1) Hemoglobin <80g/L; (2) Platelet <80×10\^9/L; (3) Neutrophils < 1.0×10\^9/L; (4) Aspartic acid aminotransferase (AST) or alanine aminotransferase (ALT) >2.5× normal upper limit, except for the correlation with the primary disease;

Egyéb

• 4. Patients with non-simple IgA nephropathy, such as diabetic nephropathy or obesity-related nephropathy.
• 6. Those who are pregnant or lactating or unwilling to take contraceptive measures.
• 16. Weight less than 50kg should be excluded;
• 17. Other researchers judge the patients unsuitable for inclusion in the study

• 1. 18 to 75 of age, male or female;
• 2. primary IgA nephropathy confirmed by renal biopsy
• 3. eGFR>30ml/min/1.73m2(calculated according to the CKD-EPI formula);
• 4. After using maximum tolerated doses of ACEI and/or ARB for 3 months, the following two points should be met:
  • 24h proteinuria ≥1g;
  • Bp<130/80 mmHg；
• 5. Serum albumin > 25g/L;
• 6. Sign the informed consent.
  • Note : It is suggested that active IgAN patients should be selected. Active IgAN is specifically defined as conforming to any of the following :
• ) intradermal augmentation ( E1 ),
• ) crescentic body 0 - 50 % ( C1 / C2 ),
• ) fibrinoid necrosis,
• ) more interstitial inflammatory cell infiltration. At the same time, the proportion of sclerosis was low ( spherical or segmental sclerosis ball < 50 % ), and interstitial fibrosis was low ( below T2 ).